Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Payment Reform: A Trend In White House Thinking
White House health reformers have pressed over the last month for payment reforms that would reward doctors and hospitals for spending less and delivering higher quality care, rather than simply providing a higher volume of services. The Wall Street Journal reports that reexamining payment systems is a hot topic among administration officials in other disciplines, too: "President Barack Obama believes you get what you pay for--in business, in health care and in teaching. And in each of those spheres, he doesn"t think the way the U.S. pays professionals is designed to get what the nation really wants and needs."
generic viagra online
Celebrity Performer Duo Receives MDA Directors' Awards
The Muscular Dystrophy Association has awarded its highest philanthropic achievement honor, the MDA Directors" Award, to two entertainment industry celebrities.
News of the day
FDA Warns Consumers Not To Eat California Prime Produce And Orange County Orchards Brands Of Pistachios
The U.S. Food and Drug Administration is warning consumers not to eat California Prime Produce and Orange County Orchards brands of pistachios repacked by Orca Distribution West Inc., Anaheim, Calif. Orca received and repacked pistachios recalled by Setton Pistachio of Terra Bella Inc., Terra Bella, Calif.
Public Health

InteKrin Therapeutics To Present At The 2009 American Diabetes Association Annual Meeting

InteKrin Therapeutics, Inc. announced it will present Phase 2a clinical data for INT131, a Selective PPAR Modulator (SPPARM), at the American Diabetes Association annual meeting in New Orleans Saturday, June 6, 2009 during the "Novel Diabetes Therapies in Development in Humans" session at 4:00 pm CDT. Dr. Alex DePaoli, Chief Medical Officer of InteKrin Therapeutics, will provide a summary of the latest clinical data supporting the design of INT131 to safely and effectively address insulin resistance in a presentation entitled "INT131: Significantly Lowers Glucose Without Typical Thiazolidinedione (TZD) Side Effects in Patients with Type 2 Diabetes." About INT131 INT131 is a next-generation insulin sensitizer currently in Phase 2b testing that addresses insulin resistance, a key etiological feature in the onset and subsequent progression of type 2 diabetes. Purposefully designed as a SPPARM, INT131 selectively modulates PPAR-gamma, thereby allowing the retention of the clinically proven anti-diabetic efficacy of PPAR gamma activation, while mitigating or eliminating the well recognized side effects of TZD full PPAR gamma agonists rosiglitazone and pioglitazone (Avandia(R) and Actos(R) respectively). About InteKrin InteKrin Therapeutics is a privately-held clinical-stage drug development company focused on diabetes, obesity and metabolic disease. InteKrin"s business strategy is to build a robust portfolio of high value products by in-licensing clinical-stage therapeutic candidates that address significant unmet medical needs and rapidly move them through critical development stages. InteKrin"s team of world-class scientific and medical experts includes veterans from several successful BioPharma organizations, internationally recognized experts in nuclear receptors and metabolism, top scientists formerly with the Food and Drug Administration and key clinical and commercialization leaders. InteKrin Therapeutics, Inc


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009